Robert R. Ruffolo, Jr

Dr. Ruffolo is President of Research and Development for Wyeth Pharmaceuticals, and corporate Senior Vice President of Wyeth. During his career in the Pharmaceutical Industry, Dr. Ruffolo played a significant role in the discovery and/or development of a number of marketed products, including carvedilol (Coreg/Kredex) for the treatment of congestive heart failure and hypertension, dobutamine (Dobutrex) for the acute management of congestive heart failure, ropinirole (Requip) for Parkinson's Disease, eprosartan (Teveten) for hypertension. Dr. Ruffolo has authored nearly 500 full-length publications and 200 abstracts, and has edited 17 books. He is currently the Editor-in-Chief of Current Opinions in Pharmacology. Dr. Ruffolo has served on the editorial boards of 28 international scientific journals. Dr. Ruffolo received a number of prestigious awards, including Chief Scientific Officer of the Year (2004), George B. Koelle Award for Scientific Excellence (2005), Lorenzini Gold Medal for Biomedical Research (1999), John Jacob Abel Award in Pharmacology (1988), Prix Galien Special Commendation for Excellence and Innovation in Research (1996), the Distinguished Alumni Award from The Ohio State University (1989). The American Society for Information Science and Technology designated Dr. Ruffolo as a Highly Cited Scientist for being among the top one-hundred most cited Pharmacologists in the world over the past two decades.

On the 30th of November, 2007, Dr. Ruffolo has received a Degree Honoris Causa in Management Engineering from the University of Catania in Sicily, Italy.